Brokers Offer Predictions for Nanobiotix FY2026 Earnings

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Stock analysts at HC Wainwright dropped their FY2026 EPS estimates for Nanobiotix in a research note issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.37 per share for the year, down from their prior estimate of $1.41. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nanobiotix’s current full-year earnings is $0.53 per share. HC Wainwright also issued estimates for Nanobiotix’s FY2027 earnings at $0.84 EPS, FY2028 earnings at $0.66 EPS and FY2029 earnings at $1.87 EPS.

NBTX has been the topic of a number of other research reports. UBS Group boosted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Guggenheim boosted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Nanobiotix Stock Down 6.6%

NASDAQ NBTX opened at $46.20 on Wednesday. The firm’s fifty day moving average price is $35.60 and its two-hundred day moving average price is $27.24. Nanobiotix has a fifty-two week low of $3.64 and a fifty-two week high of $57.14.

Nanobiotix (NASDAQ:NBTX) last posted its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million for the quarter.

Institutional Trading of Nanobiotix

Several institutional investors have recently modified their holdings of NBTX. Millennium Management LLC acquired a new stake in shares of Nanobiotix during the fourth quarter worth $390,000. Royal Bank of Canada lifted its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP acquired a new position in Nanobiotix in the fourth quarter valued at $220,000. Finally, Optiver Holding B.V. acquired a new position in Nanobiotix in the third quarter valued at $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.